Key highlights
06 June 2023 – 0 mins read
LinkedIn
Facebook
Explore more statements
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 8 Media Statements
–
06 May 2025
06 May 2025
Ipsen to present new data across four rare liver diseases at EASL, including late-breaking data in PBC and PSC
PARIS, FRANCE, 6 May 2025 – Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced that seven abstracts with new data from its rare liver disease portfolio will be presented at the European Association for the Study of the Liver (EASL) congress,…
–
13 March 2025
13 March 2025
Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s
PARIS, FRANCE, March 13th, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today it has been assigned long-term credit ratings of Baa3 by Moody’s and BBB- by S&P Global Ratings, both with a “Stable” outlook.
–
03 October 2024
03 October 2024
An update for healthcare professionals and patients on Increlex® (mecasermin) Injection
Testing statements summary
–
27 August 2024
27 August 2024
Ipsen announces sale of Priority Review Voucher for $158m
PARIS, FRANCE, 27 August 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) has entered into an agreement to sell its rare pediatric disease Priority Review Voucher (PRV) to a large global pharmaceutical company. Ipsen received the PRV coinciding with the SohonosTM…
–
29 July 2024
29 July 2024
LinkedIn
Facebook
Testing video 1
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type…
Your dedicated contacts
-
Amy Wolf
Vice-Présidente, Stratégie de la marque Corporate et Communication
-
Ioana Piscociu
Senior Manager, Media Relations
-
Related links
